{"url_path":"/sec/lctx/8-k/2026-06-12/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-12","source_url":"https://www.sec.gov/Archives/edgar/data/876343/0001193125-26-269557-index.html","accession_number":"0001193125-26-269557","cik":"0000876343","ticker":"LCTX","issuer_name":"Lineage Cell Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/876343/0001193125-26-269557-index.html","primary_entity_key":"0000876343","primary_entity_name":"Lineage Cell Therapeutics, Inc."},"word_count":205,"has_tables":true,"body_markdown":"## Item 8.01 Other Events.\n\nAs previously reported, in January 2026, the Company applied for a Clinical Trial (CLIN2) award (the “CIRM Grant”) from the California Institute for Regenerative Medicine (“CIRM”) to support continued clinical development of OPC1 for the treatment of spinal cord injuries (“SCI”). On June 9, 2026, following comments to the application received by the Company from CIRM, the Company elected to withdraw its application for the CIRM Grant. The withdrawal of the application does not impact the Company’s current and planned development of OPC1 in the ongoing DOSED (Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device) clinical study to evaluate the safety and utility of a novel spinal cord delivery device designed to administer OPC1 to the spinal parenchyma in both subacute (between 21 to 42 days following injury) and chronic (between 1 to 5 years following injury) SCI participants.\n\n##  \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nLineage Cell Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 12, 2026\n\nBy:\n\n/s/ George A. Samuel III\n\n \n\n \n\nName:\n\nTitle:\n\nGeorge A. Samuel III\nGeneral Counsel and Corporate Secretary"}